finally, the BLSOmp31 vaccine elicited an immune activation status that could be potentially compatible with effective control of the aethiological agent of canine brucellosis. consequently, further investigations will focus on the safety and efficacy of rBLSOmp31 based subcutaneous vaccination in the natural host of this disease : the dogs